July 2026
End-of-life distress
What July 2026's 6 new studies found, synthesized from the papers below. All End-of-life distress research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for End-of-life distress, existential distress, palliative, terminal illness anxiety, then ranked by relevance.
Research published in July 2026 indicates that psychedelic-assisted therapy shows promise for reducing end-of-life distress, including demoralization, anxiety, and depression, with rapid and long-lasting effects and a low risk of serious adverse events. However, evidence is preliminary, based on small samples and open-label designs, and faces barriers such as legal restrictions, knowledge gaps, and the need for standardized protocols and larger trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Screening and Supporting Spiritual Concerns in Psychedelic Assisted Therapy with Palliative Care Populations: A Narrative Review Pre-Registration 2026 | narrative review | Unclear | This pre-registration describes a narrative review aiming to determine the extent to which spiritual, existential, religious, and theological components are included in screening and treatment protocols for psychedelic-assisted therapies in seriously ill individuals; no results are reported. | |
| The potential role of psychedelics in palliative care 2026 | review | Supports | This review reports that psychedelics can produce rapid and long-lasting antidepressant and anxiolytic effects with a low risk of serious adverse events in end-of-life patients, but notes that legal restrictions and the need for larger trials and guidelines remain barriers. | |
| Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study. 2026 | open-label pilot study | 11 | Supports | In this open-label pilot, psilocybin-assisted therapy with multidisciplinary palliative care was safe, feasible, and acceptable, with 90% of dosed participants no longer meeting criteria for clinically significant demoralization and having pain scores below the enrollment threshold by study endpoint. |
| The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer 2026 | qualitative study | 11 | Mixed | Healthcare professionals expressed interest in psychedelic-assisted therapy for existential distress in cancer patients but identified knowledge gaps, barriers, and a need for more research, preferring multidisciplinary, culturally sensitive, and ethically rigorous delivery. |
| Policy pathways and historical insights: Canada's evolving approach to psychedelic access for end-of-life distress 2026 | theoretical or philosophical paper | Unclear | Argues that Canada's evolving psychedelic drug policy trajectory aligns with international trends toward cautious medicalization and regulated access to psychedelic therapies, offering an instructive case for how end-of-life frameworks and federal-provincial governance shape policy development. | |
| Reframing distress in oncology: the potential of psychedelic-assisted therapy. 2026 | review | Supports | This review reports that psychedelic-assisted therapy shows promise for improving anxiety, depression, pain-related distress, and quality of life in advanced cancer patients, but notes that evidence is limited by small sample sizes and other methodological constraints. |
This pre-registration describes a narrative review aiming to determine the extent to which spiritual, existential, religious, and theological components are included in screening and treatment protocols for psychedelic-assisted therapies in seriously ill individuals; no results are reported.
narrative review
This review reports that psychedelics can produce rapid and long-lasting antidepressant and anxiolytic effects with a low risk of serious adverse events in end-of-life patients, but notes that legal restrictions and the need for larger trials and guidelines remain barriers.
review
In this open-label pilot, psilocybin-assisted therapy with multidisciplinary palliative care was safe, feasible, and acceptable, with 90% of dosed participants no longer meeting criteria for clinically significant demoralization and having pain scores below the enrollment threshold by study endpoint.
open-label pilot study Sample size: 11
Healthcare professionals expressed interest in psychedelic-assisted therapy for existential distress in cancer patients but identified knowledge gaps, barriers, and a need for more research, preferring multidisciplinary, culturally sensitive, and ethically rigorous delivery.
qualitative study Sample size: 11
Argues that Canada's evolving psychedelic drug policy trajectory aligns with international trends toward cautious medicalization and regulated access to psychedelic therapies, offering an instructive case for how end-of-life frameworks and federal-provincial governance shape policy development.
theoretical or philosophical paper
This review reports that psychedelic-assisted therapy shows promise for improving anxiety, depression, pain-related distress, and quality of life in advanced cancer patients, but notes that evidence is limited by small sample sizes and other methodological constraints.
review
Points of agreement
- Psychedelic-assisted therapy is considered a promising intervention for end-of-life distress, including depression, anxiety, existential distress, and demoralization.
- Reported effects are rapid and may be long-lasting, with a low risk of serious adverse events.
- Current evidence is limited by small samples, methodological constraints, and legal or regulatory barriers.
- There is a need for more research, larger trials, and standardized clinical guidelines before routine integration into palliative care.
Conflicts
- No direct contradictions were reported; however, the qualitative study highlighted knowledge gaps and barriers among healthcare professionals, while reviews emphasized promise, reflecting differing perspectives on readiness for implementation.
Gaps
- Durability of effects beyond study endpoints is not established.
- Blinding and control conditions are lacking in the pilot study.
- Populations are narrow, often limited to cancer patients or end-of-life patients, with little diversity.
- Dose-response relationships and optimal protocols are not defined.
- Spiritual and existential screening and support components are not well characterized.
- Research on patients with suicidal ideation is specifically called for but not yet available.